OR

Oystein Rekdal

Chief Executive Officer

Lytix Biopharma

Oslo, Oslo


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Lytix Biopharma
Industry
biotechnology
Employees
22.0
Seniority
C suite
Annual Revenue
2400000.0

Technologies

Cloudflare DNS Outlook Microsoft Office 365 Google Font API Google Maps Nginx Vimeo Mobile Friendly Bootstrap Framework reCAPTCHA Google Maps (Non Paid Users)

Keywords

biotech cancer treatment immunotherapy host-defense peptides tumor heterogeneity t-cell response clinical-stage combination therapy molecular technology cancer immunology therapeutics antigen presentation tumor antigens peptide chemistry resistant cancer cells immune system activation biopharmaceuticals drug development oncology clinical trials preclinical studies immune modulation drug discovery research collaborations biotech investments imet cytokines peer-reviewed publications biotech platform strategic business development clinical programs partnering strategies pharmaceutical collaborations r&d science & technology life sciences financial reports shareholder information euronext growth investor relations clinical data drug efficacy cancer indications risk assessment safety profiles patient outcomes hospital & health care health care health wellness & fitness research & development

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans